Engineered Mesenchymal Stem Cells for Targeted Cancer Immunotherapy
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current combinatorial immunotherapy approaches for cancer, such as ovarian cancer, face challenges in delivering multiple therapies simultaneously to achieve maximal efficacy without significant side effects, and determining appropriate dosing and timing, while also being limited by systemic toxicity and the complex tumor microenvironment that suppresses anti-tumor immune responses.
Innovation Solution
Engineered cell circuits, specifically in mesenchymal stem cells, that deliver multiple immunomodulatory effector molecules to the tumor microenvironment, optimizing promoters, linkers, and signal peptides to enhance cancer therapy by selectively targeting tumors and modulating the immune response.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If multiple immunomodulatory effector molecules are delivered simultaneously to achieve maximal efficacy, then anti-tumor immune response is enhanced, but systemic toxicity increases
Solution Approach 1:
The patent applies local quality by engineering mesenchymal stem cells to selectively home to tumor microenvironments, delivering multiple immunomodulatory effector molecules (such as cytokines, chemokines, and immune checkpoint inhibitors) specifically to tumor sites. This localized delivery ensures enhanced anti-tumor immune response at the target site while minimizing exposure and toxicity to healthy systemic tissues.
Solution Approach 2:
The patent uses mesenchymal stem cells as intermediary carriers to deliver multiple immunomodulatory effector molecules. These stem cells act as mediators that transport therapeutic agents directly to the tumor microenvironment, enabling controlled local release of multiple molecules simultaneously while protecting systemic tissues from direct exposure and reducing overall systemic toxicity.
2Reliability
If multiple therapies are administered systemically to achieve robust efficacy, then anti-tumor activity is improved, but it becomes difficult to determine appropriate dosing and timing
Solution Approach 1:
The patent implements self-service by engineering mesenchymal stem cells with autonomous tumor-homing capabilities. These engineered cells automatically navigate to and accumulate at tumor sites without requiring external guidance or complex dosing schedules. The cells self-regulate their localization and therapeutic delivery, simplifying the overall treatment protocol and eliminating the need for complex dosing and timing determinations that would be required for multiple systemic therapies.
Solution Approach 2:
The patent merges multiple immunomodulatory effector molecules into a single engineered mesenchymal stem cell delivery system. By combining multiple therapeutic agents (such as different cytokines, chemokines, and immune modulators) within one cell platform, the patent delivers a combination therapy through a single administration, thereby achieving robust anti-tumor activity while avoiding the complexity of coordinating multiple separate systemic treatments with different dosing and timing requirements.
3Ease of operation
If a single pathway is targeted to simplify treatment, then ease of administration is improved, but efficacy against solid tumors is insufficient
Solution Approach 1:
The patent applies universality by designing mesenchymal stem cells with multi-functional capabilities to simultaneously deliver multiple types of immunomodulatory effector molecules (including cytokines, chemokines, and immune checkpoint inhibitors) through a single administration. This multi-functional delivery system maintains ease of administration like single-pathway targeting while achieving comprehensive anti-tumor efficacy by addressing multiple immune suppression pathways concurrently within the tumor microenvironment.
Data Source
AI summary
Provided herein are methods and compositions for dynamically controlling and targeting multiple immunosuppressive mechanisms in cancer. Some aspects provide cells engineered to produce multiple effector molecules, each of which modulates a different immunosuppressive mechanisms of a tumor, as well as methods of using the cells to treat cancer, such as ovarian, breast, or colon cancer.